339,461 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by SEB Asset Management AB

Key Points

• SEB Asset Management AB bought 339,461 shares of Olema Pharmaceuticals in Q1, worth about $5.06 million, and now owns roughly 0.39% of the company.
• Institutional interest in OLMA remains strong, with several other funds adding positions and hedge funds/investors owning 91.78% of the stock overall.
• Analysts are still cautiously positive: the stock carries a Moderate Buy consensus and an average price target of $44.10, though recent ratings have been mixed.

SEB Asset Management AB purchased a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 339,461 shares of the company's stock, valued at approximately $5,061,000. SEB Asset Management AB owned about 0.39% of Olema Pharmaceuticals at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of OLMA. SG Americas Securities LLC purchased a new stake in shares of Olema Pharmaceuticals in the 4th quarter valued at about $1,735,000. Jennison Associates LLC acquired a new stake in shares of Olema Pharmaceuticals in the 4th quarter valued at about $24,100,000. Hennion & Walsh Asset Management Inc. grew its stake in Olema Pharmaceuticals by 83.2% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 447,046 shares of the company's stock worth $11,176,000 after buying an additional 202,970 shares during the last quarter. Tema Etfs LLC purchased a new position in Olema Pharmaceuticals during the 4th quarter worth approximately $1,113,000. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. increased its position in Olema Pharmaceuticals by 3,237.5% during the first quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 116,812 shares of the company's stock worth $1,742,000 after buying an additional 113,312 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

Analysts Set New Price Targets

OLMA has been the subject of several research analyst reports. HC Wainwright reissued a "buy" rating on shares of Olema Pharmaceuticals in a report on Friday, May 22nd. Wolfe Research started coverage on shares of Olema Pharmaceuticals in a report on Friday, March 27th. They issued a "peer perform" rating on the stock. Guggenheim reduced their price target on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, May 13th. Wall Street Zen upgraded shares of Olema Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Sunday, July 12th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Olema Pharmaceuticals in a research report on Friday, July 17th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $44.10.

Olema Pharmaceuticals Trading Down 0.9%

Shares of OLMA stock opened at $11.49 on Thursday. The business's 50 day moving average is $11.69 and its two-hundred day moving average is $17.18. Olema Pharmaceuticals, Inc. has a twelve month low of $4.47 and a twelve month high of $36.26. The company has a market capitalization of $1.00 billion, a P/E ratio of -5.69 and a beta of 2.00. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, hitting the consensus estimate of ($0.52). Equities analysts forecast that Olema Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.